Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 26, Issue 2, 2000, Pages 161-167

  Yanik, G ^a   Levine, J E ^a   Ratanatharathorn, V ^b   Dunn, R ^a   Ferrara, J ^a,b   Hutchinson, R J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Allogeneic bone marrow transplant; Children; FK506; Graft versus host disease; Peripheral blood stem cell transplant; Tacrolimus

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; METHOTREXATE; TACROLIMUS;

ADOLESCENT; AGRANULOCYTOSIS; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HUMAN; HYPERGLYCINEMIA; HYPERTENSION; HYPOMAGNESEMIA; INFANT; LEUKEMIA; MYELODYSPLASIA; NEPHROTOXICITY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREMOR;

EID: 0033916073     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702472     Document Type: Article

References (45)

1. Kino T, Hatanaka H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249-1255.
2. Yoshimura N, Matsui S, Hamashima T et al. A new immunosuppressive agent, FK-506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. Transplant Proc 1989; 21: 1045-1047.
3. Yoshimura N, Matsui S, Hamashima T et al. Effect of a new immunosuppressive agent, FK-506, on human lymphocyte responses in vitro. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. Transplantation 1989; 47: 356-359.
4. Bishop DK, Li W. Cyclosporin A and FK-506 mediate differential effects on T cell activation in vivo. J Immunol 1992; 148: 1049-1054.
5. Shaw KT, Ho AM, Raghavan A et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995; 92: 11205-11209.
6. Mouzaki A, Rungger D. Properties of transcription factors regulating interleukin-2 gene transcription through the NFAT binding site in untreated or drug-treated naive and memory T-helper cells. Blood 1994; 84: 2612-2621.
7. Fung JJ, Eliasziw M, Todo S et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996; 183: 117-125.
8. Shapiro R, Jordan ML, Scantlebury VP et al. Tacrolimus in renal transplantation. Transplant Proc 1996; 28: 2117-2118.
9. Shapiro R, Scantlebury VP, Jordan ML et al. Tacrolimus in pediatric renal transplantation. Transplantation 1996; 62: 1752-1758.
10. Armitage JM, Kormos RL, Morita S et al. Clinical trial of FK-506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992; 54: 205-211.
11. Fay JW, Wingard JR, Antin JH et al. FK-506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996; 87: 3514-3519.
12. Nash RA, Etzioni R, Storb R et al. Tacrolimus (FK-506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746-3753.
13. Kanamaru A, Takemoto Y, Kakishita E et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK-506 BMT Study Group. Bone Marrow Transplant 1995; 15: 885-889.
14. Hiraoka AF. Results of a phase III study on prophylactic use of FK506 for acute GVHD compared with cyclosporin in allogeneic bone marrow transplantation. Blood 1997; 90: 561a.
15. Uberti JP, Silver SM, Adams PT et al. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1997; 19: 1233-1238.
16. Uberti JP, Scalzo A. Hammelef K et al. Allogeneic peripheral blood stem cell transplantation for hematologic malignancy: the efficacy of tacrolimus in the prevention of acute graft-versus-host disease. Blood 1997; 90: 393b (Abstr. 4514).
17. Przepiorka D, Ippoliti C, Khouri I et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation 1996; 62: 1806-1810.
18. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
19. Nash RA, Pineiro LA. Storb R et al. FK-506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88: 3634-3641.
20. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-4389.
21. Devine SM, Geller RB, Lin LB et al. The outcome of unrelated donor marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low-dose methotrexate for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 1997; 3: 25-33.
22. Nash RA, Antin J, Karanes C et al. Phase III study comparing tacrolimus (FK506) with cyclosporine (CSP) for prophylaxis of acute graft-versus-host disease (GVHD) after marrow transplantation from unrelated donors. Blood 1997; 90: 561a.
23. Wingard JO, Nash RA, Przepiorka D et al. Relationship of tacrolimus (Prograf, FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Bone Marrow Transplant 1998; 4: 157-163.
24. Kochler MT, Howrie D, Mirro J et al. FK-506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. Bone Marrow Transplant 1995; 15: 895-899.
25. Przepiorka D, Petropoulos D, Mullen CA et al. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. Bone Marrow Transplant 1999; 23: 1291-1296.
26. Jones JR, Lee KSK. Beschorner WE et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1997; 44: 778-783.
27. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295-304.
28. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
29. McCauley J. The nephrotoxicity of FK506 as compared with cyclosporine. Curr Opin Nephrol Hypertens 1993; 2: 662-669.
30. Wijdicks EF, Weisner RH, Dahlke LJ et al. FK506-induced neurotoxicity in liver transplantation. Ann Neurol 1994; 35: 498-501.
31. Mueller AR, Platz KP, Bechstein WO et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58: 155-170.
32. Small SL, Fukui MD, Bramblett GT et al. Immunosuppression-induced leukoencephlopathy from tacrolimus (FK-506). Ann Neurol 1996; 40: 575-580.
33. Mach-Pascual S. Samii K, Beris P. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. Am J Hematol 1996; 52: 310-312.
34. Kaplan B, Wang Z, Abecassis MM et al. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. Transplantation 1996; 62: 1174-1175.
35. Andoh TF, Burdmann EA, Fransechini N et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK-506. Kidney Int 1996; 50: 1110-1117.
36. Peters DH, Fitton A, Plosker GL et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746-794.
37. Ichihashi T, Naoe T, Yoshida H et al. Haemolytic oraemic syndrome during FK506 therapy. Lancet 1992; 340: 60-61.
38. Gharpure VS, Devine SM, Holland HK et al. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. Bone Marrow Transplant 1995; 16: 715-716.
39. Zikos P, Van Lint MT. Frassoni F et al. Low transplant mortality in allogeneic bone marrow transplantation for acute leukemia: a randomized study of low-dose cyclosporin vs low-dose cyclosporin and low-dose methotrexate. Blood 1998; 91: 3503-3508.
40. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine vs cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
41. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
42. Peters C, Minkov M, Gadner H et al. Proposal for standard recommendations for prophylaxis of graft-versus-host disease in children. Bone Marrow Transplant 1998; 21 (Suppl. 2): S57-S60.
43. Stockschlader M, Storb R, Pepe M et al. A pilot study of low dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br J Haematol 1992; 80: 49-54.
44. Gluckman E, Esperou H, Devergie A et al. Pediatric bone marrow transplantation for leukemia and aplastic anemia. Report of 222 cases transplanted in a single center. Nouv Rev Fr Hematol 1989; 31: 111-114.
45. Ratanatharathorn V. Antin J, Karanes C et al. Relationship of tacrolimus and cyclosporine blood concentrations to the risk of acute GVHD and renal dysfunction after unrelated donor marrow transplantation. Blood 1998; 92: 449a.